Ascendis Pharma AS (NASDAQ:ASND) shares traded down 1.2% during mid-day trading on Friday . The company traded as low as $19.39 and last traded at $19.40, with a volume of 135,386 shares trading hands. The stock had previously closed at $19.64.

A number of research analysts have issued reports on the stock. Leerink Swann restated a “buy” rating on shares of Ascendis Pharma AS in a research note on Friday. Zacks Investment Research upgraded shares of Ascendis Pharma AS from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Monday, August 15th.

The firm has a 50 day moving average price of $15.39 and a 200-day moving average price of $15.85. The firm’s market cap is $487.48 million.

Ascendis Pharma AS (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. Equities research analysts forecast that Ascendis Pharma AS will post ($3.15) EPS for the current fiscal year.

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.